These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 17714966

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia.
    Watanabe T, Miyazaki A, Katagiri T, Yamamoto H, Idei T, Iguchi T.
    J Am Geriatr Soc; 2005 Oct; 53(10):1748-53. PubMed ID: 16181175
    [Abstract] [Full Text] [Related]

  • 3. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
    Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H, LEADe investigators.
    Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
    [Abstract] [Full Text] [Related]

  • 4. The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease.
    Obermayr RP, Mayerhofer L, Knechtelsdorfer M, Mersich N, Huber ER, Geyer G, Tragl KH.
    Exp Gerontol; 2005 Mar; 40(3):157-63. PubMed ID: 15763392
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group.
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [Abstract] [Full Text] [Related]

  • 7. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
    Tanaka M, Namiki C, Thuy DH, Yoshida H, Kawasaki K, Hashikawa K, Fukuyama H, Kita T.
    J Neurol Sci; 2004 Oct 15; 225(1-2):135-41. PubMed ID: 15465097
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease.
    Yamagata B, Watanabe T, Tomioka H, Kobayashi H, Nakano Y, Mimura M.
    Regul Pept; 2010 Aug 09; 163(1-3):137-42. PubMed ID: 20451565
    [Abstract] [Full Text] [Related]

  • 10. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.
    Neurology; 2007 Jul 31; 69(5):459-69. PubMed ID: 17664405
    [Abstract] [Full Text] [Related]

  • 11. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease.
    Hashimoto M, Yatabe Y, Kaneda K, Honda K, Ikeda M.
    Psychogeriatrics; 2009 Dec 31; 9(4):196-203. PubMed ID: 20377821
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
    López-Pousa S, Olmo JG, Franch JV, Estrada AT, Cors OS, Nierga IP, Gelada-Batlle E.
    Age Ageing; 2006 Jul 31; 35(4):365-71. PubMed ID: 16788079
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A, Gauthier S, Perdomo C.
    Int J Geriatr Psychiatry; 2007 Aug 31; 22(8):806-12. PubMed ID: 17199235
    [Abstract] [Full Text] [Related]

  • 15. Cognitive predictors of donepezil therapy response in Alzheimer disease.
    Saumier D, Murtha S, Bergman H, Phillips N, Whitehead V, Chertkow H.
    Dement Geriatr Cogn Disord; 2007 Aug 31; 24(1):28-35. PubMed ID: 17495473
    [Abstract] [Full Text] [Related]

  • 16. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
    Tinklenberg JR, Kraemer HC, Yaffe K, Ross L, Sheikh J, Ashford JW, Yesavage JA, Taylor JL.
    Am J Geriatr Psychiatry; 2007 Nov 31; 15(11):953-60. PubMed ID: 17974866
    [Abstract] [Full Text] [Related]

  • 17. Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD).
    Giordano M, Dominguez LJ, Vitrano T, Curatolo M, Ferlisi A, Di Prima A, Belvedere M, Barbagallo M.
    Arch Gerontol Geriatr; 2010 Nov 31; 51(3):245-9. PubMed ID: 19969381
    [Abstract] [Full Text] [Related]

  • 18. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.
    Wattmo C, Hansson O, Wallin AK, Londos E, Minthon L.
    Dement Geriatr Cogn Disord; 2008 Nov 31; 26(3):203-11. PubMed ID: 18769065
    [Abstract] [Full Text] [Related]

  • 19. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
    Nozawa M, Ichimiya Y, Nozawa E, Utumi Y, Sugiyama H, Murayama N, Iseki E, Arai H.
    Psychogeriatrics; 2009 Jun 31; 9(2):50-5. PubMed ID: 19604325
    [Abstract] [Full Text] [Related]

  • 20. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C, Masullo C.
    Dement Geriatr Cogn Disord; 2005 Jun 31; 20(4):254-61. PubMed ID: 16103669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.